Abiraterone for metastatic, hormone sensitive, prostate cancer

Bookmark and Share
Published: 21 Jul 2017
Views: 1415
Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA

Prof Petrylak talks with ecancer at the Best of ASCO 2017 meeting in Miami about the early use of the CYP17A1 inhibitor, abiraterone, for patients with metastatic, hormone sensitive, prostate cancer.

He goes on to discuss the data from, and the differences between, the STAMPEDE and LATITUDE trials.

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James discuss the latest in prostate cancer, in particular the STAMPEDE and LATITUDE trials here.